Oklo (OKLO) stock still trades on long-term promise, but the story is starting to shift.
For much of the past year, the focus was on AI-driven power demand and the idea that advanced nuclear could become a key part of that buildout. That narrative helped push the stock higher, even as the company remained pre-revenue.
Now, the emphasis is changing.
The latest update from the U.S. Department of Energy makes it clear that licensing progress, fuel access, and financing will determine the stock’s long-term outcome.
Oklo still needs approval from regulators, a reliable supply of HALEU fuel, and a signed long-term power agreement before its first project can move toward commercialization.
The key question now is pretty straightforward: Can Oklo execute on those milestones before it needs to raise more capital?
(Note: Traditional valuation metrics like P/E and EBITDA multiples are not meaningful yet due to negative earnings and pre-revenue status.)
Stats from TIKR.com.
Oklo’s March 17, 2026 update announced that the company had just cleared an early regulatory step with the Department of Energy for its isotope reactor project in Texas.
The Nuclear Safety Design Agreement, or NSDA, is part of a faster approval pathway the DOE is using to help get new nuclear projects off the ground more quickly.
In practical terms, it means the government has signed off on the project’s initial safety approach.
That allows Oklo to move into the next phase, where it submits more detailed safety analysis and design work for review.
More Tech Stocks:
With no commercial plant in operation, the main milestones that matter now are NRC progress and a viable HALEU supply path.
Both are required before Aurora can move forward.
Aurora is Oklo’s first planned commercial reactor, which the company hopes to deploy as its initial revenue-generating project.
CEO Jacob DeWitte says, “DOE’s pathway for the Aurora-INL supports a stepwise approach to deploying our first powerhouse while we continue progressing our engagement for future commercial licensing by the US Nuclear Regulatory Commission.”
Until licensing and fuel are secured, Aurora remains a concept rather than something lenders can finance or investors can value with confidence.
Story Continues
The challenge for a HALEU supply plan extends beyond Oklo. HALEU remains a known bottleneck across the advanced nuclear sector, with supply still constrained and heavily dependent on government-backed initiatives.
That makes regulatory timing and fuel availability the two biggest variables for when Oklo can generate its first revenue and whether its projects can be financed on reasonable terms.
Analysts have also pointed out that early demand signals need to be converted into firm agreements before projects can be financed.
Interest from AI and data-center customers has supported the stock, which has nearly doubled in the past year despite the company being pre-commercial. But revenue visibility remains limited without a publicly disclosed long-term power purchase agreement.
Analyst sentiment is starting to split as expectations reset.
Craig-Hallum lowered its price target on Oklo to $71 from $87 and kept a Hold rating, citing growing concerns about the company’s capital needs.
Needham also cut its target, dropping it to $73 from $135 as it scaled back its deployment outlook, though the firm still rates the stock a Buy.
On the other hand, William Blair reiterated an Outperform rating, highlighting continued progress on Oklo’s Aurora reactor, including an initial design approval from the Department of Energy.
Oklo’s CEO, Jacob DeWitte, has emphasized strong demand from data-center and industrial customers, but the market is still waiting for a major power deal to be signed and disclosed.
Oklo is pre-revenue so the company’s valuation is being determined by milestones. Future Publishing via Getty Images ·Future Publishing via Getty Images
Financing is now the next major pressure point.
Oklo’s latest disclosures brought renewed attention to funding risk, with management indicating that additional capital may be needed before the company generates its first commercial revenue.
That raises the risk of dilution and higher capital costs as Oklo funds license, develop, and construct without operating cash flow.
Recent results also added pressure, with Q4 2025 EPS of -$0.27, below expectations.
Oklo was direct in its update, stating it may need additional financing to support plant construction and growth. The key issue is sequencing.
If the company can line up project finance and strategic capital in the right order, it can limit dilution. If not, it may need to raise equity before commercialization gains traction.
Clear progress with NRC licensing that shortens the Aurora deployment timeline
A credible HALEU fuel supply agreement that removes a major bottleneck
A disclosed long-term power purchase agreement with a defined price and duration
New data-center or industrial contracts that convert pipeline into backlog
Strategic capital or project financing that reduces reliance on equity dilution
Licensing delays that push out revenue timing and project economics
HALEU shortages that stall deployment even if permits advance
Equity issuance at unfavorable terms before commercialization
Customer interest failing to convert into a signed, financeable power deal
Rising development and construction costs that weaken returns
Oklo remains a pre-revenue company, with valuation driven by execution milestones rather than financial results.
NRC licensing progress and HALEU fuel access are the key gating items for first revenue.
AI-driven demand is real, but still lacks a signed, financeable power agreement.
Management flagged the need for additional financing, raising dilution risk.
What matters now:
Can Oklo secure fuel and regulatory approval on time?
Can it sign a bankable long-term power deal?
Can it fund development without heavy dilution?
Related: Longtime oil analyst sends dire oil price message
This story was originally published by TheStreet on Mar 28, 2026, where it first appeared in the Investing section. Add TheStreet as a Preferred Source by clicking here.
Metropolis Healthcare has reported a robust performance in the fourth quarter, with strong growth across revenue, patient volumes, and profitability,...
